PYC Therapeutics kicks off Phase 1b MAD for PKD with first patient dosed in PYC-003; data due CY27, paving the way to registrational Phase 2/3 and NDA. The MAD study aims to establish safety and ...
This raise will set the company up for years. With PYC's value sitting at $944.8 million at the close of trade on Friday, the raise will grow the size of the company by 69.2% in one fell swoop. The ...
PYC Therapeutics, a developer of RNA therapies for genetic diseases and capitalised at $933 million on the ASX, confirmed a $653 million equity raising on Monday morning after Street Talk revealed the ...
Game decompilations have been in the news on and off again for quite some time. It’s the act of reverse engineering games to run natively on PC (or any hardware, in theory). Now, there’s potential for ...
A look at the shareholders of PYC Therapeutics Limited (ASX:PYC) can tell us which group is most powerful. The group holding the most number of shares in the company, around 45% to be precise, is ...
Potential PYC Therapeutics Limited (ASX:PYC) shareholders may wish to note that the CEO & Executive Director, Rohan Hockings, recently bought AU$200k worth of stock, paying AU$1.50 for each share.
PYC Therapeutics has built a pipeline of drug candidates addressing rare genetic diseases, with three assets now in clinical stages. The company’s strategy centers on using RNA therapeutics to ...
Hello, I'm keni(@keni_1997). This article is a Python decompilation guide for developers in a desperate situation like me, who are thinking, "I deleted my Python source code... I don't have a backup..
The dosing of patients with polycystic kidney disease is set to begin this month. Credit: SewCreamStudio / Shutterstock. PYC Therapeutics is set to begin Part B in its single ascending dose (SAD) ...
Community driven content discussing all aspects of software development from DevOps to design patterns. When you install Java, the JDK comes with a number of helpful utilities packed within the ...
PYC Therapeutics held a type B meeting with the FDA to discuss NDA requirements for VP-001, targeting retinitis pigmentosa type 11. Phase 1/2 studies of VP-001 have shown improvements in visual acuity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results